title: Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.
authors.forename: K
authors.initials: K
authors.lastname: Amarasinghe
authors.forename: C
authors.initials: C
authors.lastname: Dalley
authors.forename: I
authors.initials: I
authors.lastname: Dokal
authors.forename: A
authors.initials: A
authors.lastname: Laurie
authors.forename: V
authors.initials: V
authors.lastname: Gupta
authors.forename: J
authors.initials: J
authors.lastname: Marsh
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D019871:Dyskeratosis Congenita / Q000150:complications* / Q000628:therapy*; D017809:Fatal Outcome; D006471:Gastrointestinal Hemorrhage; D006801:Humans; D008297:Male; D019172:Transplantation Conditioning / Q000379:methods*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D014740:Vidarabine; C024352:fludarabine